PAVmed Inc.
PAVMNasdaq
$5.93
↓ -1.6%Jul 17 close · end-of-day
Price
1Y↓ -65.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$9.4M
Enterprise Value
$2.9M
P/E
—
P/S
110.2
P/B
0.2
EV/EBITDA
—
PEG
—
FCF Yield
-67.2%
Dividend Yield
—
Revenue (TTM)
$85,000.00
Net Income (TTM)
-$22.8M
Free Cash Flow (TTM)
-$6.3M
Gross Margin
—
Operating Margin
-28700.0%
Net Margin
-26825.9%
ROE
-57.7%
ROIC
-58.3%
Debt / Equity
—
Net Cash
$6.5M
Return 1Y
-67.1%
Company profile
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE)
- CEO
- Lishan Aklog
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 90
- Headquarters
- New York
- Website
- pavmed.com
Management & directors
- Aklog LishanChairman and CEO
- Gordon Michael AdamGeneral Counsel
- Lee Victoria Tou-HoChief Medical Officer
- Mcgrath Dennis MPresident and CFO
- O'Neil ShaunChief Operating Officer
Roles derived from SEC Form 4 filings.
Earnings
PAVM Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$22,000.00↑ +175.0%
Diluted EPS-$4.42↓ -143.8%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $500,000.00 | $377,000.00 | $2.5M | $3.0M | $71,000.00 |
| Gross profit | — | -$85,000.00 | — | — | — | — |
| Operating income | -$23.4M | -$54.4M | -$91.1M | -$68.8M | -$44.5M | -$21.8M |
| Net income | -$34.3M | -$50.3M | -$89.0M | -$66.3M | $32.0M | -$3.8M |
| Diluted EPS | — | — | -$15.03 | -$9.16 | $14.90 | -$5.63 |
| Operating cash flow | -$21.9M | -$40.6M | -$71.0M | -$52.0M | -$33.6M | -$5.2M |
| Free cash flow | -$22.0M | -$42.1M | -$72.5M | -$52.3M | -$33.6M | -$5.2M |
| Gross margin | — | -17.0% | — | — | — | — |
| Operating margin | — | -10878.6% | -24161.0% | -2751.8% | -1482.9% | -30712.7% |
| Net margin | — | -10069.4% | -23602.9% | -2650.8% | 1065.5% | -5315.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0M | $1.0M | $0.00 | $8,000.00 | $6,000.00 | $5,000.00 | $52,000.00 | $22,000.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$13.7M | -$11.6M | -$5.2M | -$5.4M | -$4.7M | -$4.8M | -$6.8M | -$8.0M |
| Net income | -$10.8M | $64.4M | -$6.4M | $19.0M | -$11.9M | -$5.4M | -$5.4M | -$60,000.00 |
| Diluted EPS | -$1.19 | $1.44 | $17.27 | $10.10 | -$0.74 | -$0.29 | -$14.70 | -$4.42 |
| Operating cash flow | -$11.7M | -$8.9M | $94,000.00 | -$1.6M | -$1.2M | -$896,000.00 | -$1.6M | -$2.6M |
| Free cash flow | -$11.7M | -$8.9M | $90,000.00 | -$1.6M | -$1.2M | -$899,000.00 | -$1.6M | -$2.6M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -1368.4% | -1157.8% | — | -68075.0% | -78583.3% | -96880.0% | -13078.8% | -36522.7% |
| Net margin | -1082.7% | 6439.9% | — | 237100.0% | -198683.3% | -107660.0% | -10457.7% | -272.7% |
Company news
May 15, 2026
- 65d agoPAVmed Inc (PAVM) Q1 2026 Earnings Call Highlights: Strategic Restructuring and Growth ...finance.yahoo.com
- 66d agoPAVmed (PAVM) Q4 2025 Earnings Transcriptfool.com
- 66d agoPAVmed Inc. (PAVM) Reports Q1 Loss, Lags Revenue Estimatesfinance.yahoo.com
- 66d agoPAVmed Provides Business Update and Reports First Quarter 2026 Financial Resultsfinance.yahoo.com
May 14, 2026
May 13, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-04-02 | Lee Victoria Tou-ho· Chief Medical Officer | Award | 70,000 | $0.00 | $0.00 | filing |
| 2026-04-02 | Aklog Lishan· Chairman and CEO | Award | 350,000 | $0.00 | $0.00 | filing |
| 2026-04-02 | MCGRATH DENNIS M· President and CFO | Award | 180,000 | $0.00 | $0.00 | filing |
| 2026-04-02 | Glennon Michael J | Award | 13,930 | $0.00 | $0.00 | filing |
| 2026-04-02 | Baxter Timothy E | Award | 13,930 | $0.00 | $0.00 | filing |
| 2026-04-02 | White Debra | Award | 13,930 | $0.00 | $0.00 | filing |
| 2026-04-02 | Sparks Ronald M | Award | 13,930 | $0.00 | $0.00 | filing |
| 2026-04-02 | Agrawal Sundeep | Award | 13,930 | $0.00 | $0.00 | filing |
| 2026-04-02 | Gordon Michael Adam· General Counsel | Award | 110,000 | $0.00 | $0.00 | filing |
| 2026-04-02 | O'Neil Shaun· Chief Operating Officer | Award | 110,000 | $0.00 | $0.00 | filing |
| 2025-09-30 | Sparks Ronald M | Award | 150,000 | $0.00 | $0.00 | filing |
| 2025-09-30 | White Debra | Award | 150,000 | $0.00 | $0.00 | filing |
| 2025-09-30 | Baxter Timothy E | Award | 150,000 | $0.00 | $0.00 | filing |
| 2025-09-30 | Glennon Michael J | Award | 150,000 | $0.00 | $0.00 | filing |
| 2025-09-30 | Agrawal Sundeep | Award | 150,000 | $0.00 | $0.00 | filing |
| 2025-09-30 | Gordon Michael Adam· General Counsel | Award | 150,000 | $0.00 | $0.00 | filing |
| 2025-09-30 | MCGRATH DENNIS M· President and CFO | Award | 150,000 | $0.00 | $0.00 | filing |
| 2025-09-30 | Aklog Lishan· Chairman and CEO | Award | 150,000 | $0.00 | $0.00 | filing |
| 2025-09-30 | O'Neil Shaun· Chief Operating Officer | Award | 150,000 | $0.00 | $0.00 | filing |
Latest 19 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.